Benjamin F. Edwards & Company, Inc. Collegium Pharmaceutical, Inc Transaction History

Benjamin F. Edwards & Company, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 06, 2020	SELL	$10.7 - $22.24 $64,638 - $134,351	-6,041 Closed	0 $0
Q3 2019 Nov 05, 2019	BUY	$10.16 - $13.28 $15,240 - $19,920	1,500 Added 33.03%	6,041 $69,000
Q1 2019 May 15, 2019	SELL	$13.58 - $18.72 $19,813 - $27,312	-1,459 Reduced 24.32%	4,541 $69,000
Q3 2018 Oct 29, 2018	BUY	$14.16 - $24.3 $63,720 - $109,350	4,500 Added 300.0%	6,000 $88,000
Q2 2018 Jul 19, 2018	SELL	$21.79 - $28.29 $152,530 - $198,030	-7,000 Reduced 82.35%	1,500 $36,000
Q1 2018 Apr 17, 2018	BUY	$18.15 - $29.21 $18,150 - $29,210	1,000 Added 13.33%	8,500 $217,000
Q4 2017 Jan 17, 2018	BUY	$9.3 - $19.14 $32,550 - $66,990	3,500 Added 87.5%	7,500 $138,000
Q3 2017 Oct 24, 2017	BUY	$9.15 - $11.97 $36,600 - $47,880	4,000	4,000 $42,000

256

38.6M

100K

21.1K

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.05B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

Get notified when there are updates to the investment portfolio of Benjamin F. Edwards & Company, Inc., based on Form 13F filings with the SEC.

Stay updated on Benjamin F. Edwards & Company, Inc. with notifications on news.